NYSE$GMED
Globus Medical Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Globus Medical's Q4 2023 results were announced, showcasing significant revenue growth due to the NuVasive merger.
Globus Medical reported a significant increase in worldwide net sales for Q4 2023, driven by the merger with NuVasive and increased volume of spine product sales and enabling technology volume. GAAP net income and EPS decreased, while non-GAAP net income and EPS increased. The company reaffirms its full year 2024 revenue and non-GAAP EPS guidance.
- Worldwide net sales increased by 124.6% to $616.5 million.
- GAAP net income was $15.0 million.
- GAAP diluted EPS was $0.11, and non-GAAP diluted EPS was $0.60.
- Non-GAAP adjusted EBITDA was $170.0 million, representing 27.6% of net sales.
Headline financials
Revenue & EPS history
Globus Medical · Revenue · Quarterly
$617M
Revenue by segment
Globus Medical · $375M total across 2 segments · Q3 2023
- Musculoskeletal Solutions$347M+51.0%92.6%
- Enabling Technologies$27.7M+14.8%7.4%
Forward guidance
The Company reaffirms its full year 2024 revenue guidance range of $2.450 billion to $2.475 billion and fully diluted non-GAAP earnings per share range between $2.68 to $2.70.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+0.8%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.9%
Avg return
30 days after
57%
34 / 60 earnings
Positive
+36.0%
Q3 2025
Best reaction
-23.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -14.6% | -10.4% | |
| Q4 2025 | +4.6% | +2.1% | -8.8% | |
| Q3 2025 | +36.0% | +37.3% | +47.6% | |
| Q1 2025 | -23.0% | -19.7% | -17.3% | |
| Q4 2024 | -4.6% | -4.9% | -12.5% | |
| Q3 2024 | +10.7% | +8.2% | +11.2% | |
| Q2 2024 | +4.0% | +8.0% | +4.4% | |
| Q1 2024 | +22.8% | +28.7% | +31.6% | |
| Q4 2023 | +2.2% | +4.6% | -3.1% | |
| Q3 2023 | -1.4% | -5.1% | -2.5% | |
| Q2 2023 | -5.0% | -4.8% | -9.1% | |
| Q1 2023 | +2.9% | -0.3% | -1.8% | |
| Q4 2022 | -1.2% | -21.9% | -29.2% | |
| Q3 2022 | -4.2% | +9.4% | +11.5% | |
| Q2 2022 | +5.4% | +6.9% | -2.4% | |
| Q1 2022 | +0.1% | +5.2% | +0.1% | |
| Q4 2021 | -3.1% | -3.7% | +1.3% | |
| Q3 2021 | +0.2% | -4.3% | -19.4% | |
| Q2 2021 | -3.3% | -3.0% | +1.3% | |
| Q1 2021 | +3.1% | +3.0% | -0.9% | |
| Q4 2020 | -5.7% | -5.2% | -10.2% | |
| Q3 2020 | +2.4% | +3.5% | +16.9% | |
| Q2 2020 | +18.5% | +13.4% | +13.3% | |
| Q1 2020 | +8.1% | +0.6% | +21.4% | |
| Q4 2019 | -2.1% | -9.7% | -29.0% | |
| Q3 2019 | +3.6% | +4.2% | +8.2% | |
| Q2 2019 | +9.9% | +6.1% | +12.0% | |
| Q1 2019 | -1.9% | -2.0% | -11.0% | |
| Q4 2018 | +0.2% | -2.2% | -0.3% | |
| Q3 2018 | -8.7% | -9.9% | -19.4% | |
| Q2 2018 | +4.7% | +1.7% | +3.5% | |
| Q1 2018 | -3.4% | +0.7% | +12.6% | |
| Q4 2017 | +0.5% | -1.8% | +2.2% | |
| Q3 2017 | +9.8% | +19.7% | +24.3% | |
| Q2 2017 | -5.2% | -3.7% | -1.7% | |
| Q1 2017 | +4.9% | +1.0% | +4.7% | |
| Q4 2016 | -3.1% | -2.1% | +2.5% | |
| Q3 2016 | -5.6% | -4.9% | +7.1% | |
| Q2 2016 | -14.3% | -11.7% | -13.1% | |
| Q1 2016 | -9.4% | — | — | |
| Q4 2015 | +4.2% | — | — | |
| Q3 2015 | +12.3% | — | — | |
| Q2 2015 | +2.5% | — | — | |
| Q1 2015 | +4.8% | — | — | |
| Q4 2014 | -0.9% | — | — | |
| Q3 2014 | +7.0% | — | — | |
| Q2 2014 | -16.8% | — | — | |
| Q1 2014 | +6.1% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q3 2013 | +7.1% | — | — | |
| Q2 2013 | +2.3% | — | — | |
| Q1 2013 | +7.9% | — | — | |
| Q1 2011 | +0.4% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q4 2012 | +5.8% | — | — | |
| Q3 2011 | -20.7% | — | — | |
| Q3 2012 | -16.2% | — | — | |
| Q4 2011 | -0.7% | — | — | |
| Q2 2011 | -0.7% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro